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I would like to thank Dr. Hoppe and colleagues for their recent
study published in Seizure examining vagus nerve stimulation
(VNS) versus ‘‘best drug therapy’’ in medically refractory epilepsy
patients.1 However, I have concerns regarding the authors’
methodology and conclusions. In this retrospective matched pairs
case–control study, 20 intractable epilepsy patients who received
VNS in addition to best medical therapy experienced no additional
therapeutic beneﬁt after >2 years compared to 20 individuals who
received best medical therapy alone. Both groups were retrospec-
tively selected from a signiﬁcantly larger pool of patients found to
be poor candidates for resective epilepsy surgery after having
failed medical therapy. Thus, the essence of the question posed is:
do patients who fail best drug therapy beneﬁt more from further
best drug therapy or from VNS? As both groups experienced
clinical improvement in this study, with lower seizure frequency
and improved psychological outcome, the authors imply VNS is no
better than best medical therapy alone for medically refractory
epilepsy. This sentiment is also reﬂected in Dr. Hoppe’s recent
editorial in Seizure provocatively entitled ‘‘Vagus nerve stimula-
tion: Urgent need for the critical reappraisal of clinical effective-
ness.’’2 My concerns involve study design, equivalency of the two
patient groups, inﬂated outcomes in the control group, and wider
implications of over interpreting a spurious ﬁnding.
The authors argue that while nearly all previous VNS patient
studies have shown a degree of efﬁcacy, those investigations did
not adequately examine therapeutic effectiveness, as they did not
contain a control group. What is not clear, however, is why control
patients in this study – those receiving best drug therapy alone –
improved so dramatically during the period of observation. Does
best medical therapy truly result in a >50% decrease in seizure
frequency in >60% of patients who are already medically
refractory? It is well documented that after failing 2 or more
antiepileptic medications, intractable epilepsy patients are unfor-
tunately unlikely to achieve seizure freedom with additional
medication trials.3,4 And while several new anti-seizure medica-
tions have become available since 1990,5 these novel agents have
had only a modest impact on the rate of intractable epilepsy.6–8
One potential explanation for the apparent success of best drug
therapy described by Hoppe et al. is that the patients were not
already receiving ‘‘best drug therapy’’ before the study began.
What is far more likely, however, is that the exceedingly favorable
outcomes in the control group represent a spurious ﬁnding
resulting from study design issues and inequivalent patient
groups.
Among intractable epilepsy patients found to be poor
candidates for resective surgery by Hoppe et al., 180 individuals
received VNS while more than 500 patients received continued
best drug therapy. Yet, only 40 of these >680 patients were
selected for retrospective comparison. While the authors pursued1059-1311/$ – see front matter  2013 British Epilepsy Association. Published by Else
http://dx.doi.org/10.1016/j.seizure.2013.02.015this approach in hopes of creating two well-matched patient
cohorts, it greatly under-samples available patient data, and in
my opinion, does not achieve this goal. The authors report no
statistical differences in terms of demographics and general
characteristics between these two patient groups, but this is
inherently expected, as the groups were modeled as such. But
the most important difference between the two patients groups
is that something ultimately led to the physician–patient
decision to pursue VNS in one group, but not the other.
Furthermore, the authors report that patients who received VNS
had signiﬁcantly greater seizure severity and frequency than
those in the best drug therapy group. This is a critical confounder
that may have inﬂuenced the decision to pursue VNS. There
were likely other reasons for choosing VNS in some patients but
not others that are unknowable retrospectively, yet may be of
importance. Finally, what deﬁnes the beginning of the study is
easily discernible for VNS-implanted patients, but for control
patients represents an arbitrary point on a continuum of ongoing
‘‘best drug therapy.’’ These problems make data interpretation
difﬁcult.
Another concern I have involves the wider potential implication
of erroneously inﬂating the efﬁcacy of ‘‘best drug therapy’’ in
medically refractory epilepsy patients. If dramatic clinical im-
provement can be expected in >60% of intractable epilepsy
patients with continued best drug therapy alone, why consider
resective epilepsy surgery? Resection is a potentially curative
treatment option in some focal epilepsy patients, though certainly
not without risk. But hesitating based solely on the data presented
by Hoppe et al. would be a mistake. Intractable seizures are
associated with cognitive and neuropsychological impairment,
diminished quality of life, and increased risk of death.9 In
localizable epilepsy, early surgical evaluation is supported by
class I evidence and national guidelines.10–12 Given the current
underutilization of resective epilepsy surgery,4,13 the accuracy of
treatment success rates used to make decisions in epilepsy
treatments is of utmost importance.
Based on their data interpretation, Hoppe et al. imply that VNS
does not have clinical effectiveness beyond medical therapy. VNS is
not without problems, as properly delineated by Hoppe et al.,
including treatment failure, surgical complications, device-site
infection, incompatibility with MRI, and others. Therefore, if it is
truly not effective, it should not be used, and the 100,000 implants
performed thus far may be thrown into question. Indeed, VNS is
not a replacement for resective epilepsy surgery, as nearly half of
patients do not receive worthy clinical beneﬁt from VNS, and
complete seizure-freedom is rare.14 Nevertheless, numerous
studies have consistently demonstrated that seizure frequency
is diminished greater than 50% in half or more of patients treated
with VNS.15 In appropriate patients with disabling seizures who
are not favorable candidates for resection, this real chance for
improvement makes VNS a reasonable treatment option to
consider.vier Ltd. All rights reserved.
Letter to the Editor / Seizure 22 (2013) 409–410410In the end, the ultimate test of a treatment’s clinical effectiveness
is not a retrospective cohort study, or a systematic review, or the
experience of a biased provider. It is a blinded, randomized-
controlled trial. Three such trials have examined VNS, demonstrat-
ing signiﬁcant clinical improvement with treatment when
compared to sham stimulation.16–18 I do applaud the continued
scientiﬁc skepticism and worthy pursuit of Hoppe et al., as further
exploration of the clinical effectiveness of VNS and alternative
epilepsy treatments is needed. However, once a speciﬁc question has
been addressed by a randomized-controlled trial, as in this case, a
serious challenge to it should be based in another such trial.
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